Brazil Steps Forward on Implant Price-Monitoring Plan

article image

Device industry officials who are engaged in Brazil affairs praise the country’s regulatory agency, ANVISA, for employing a rigorous rule-making process to develop a policy for monitoring orthopedic implant prices to help counter corruption, while steering clear of pursuing direct price controls.

Device industry advocates say they are pleased with Brazil’s new plans for an implant price-monitoring initiative, both for what it is, and what it is not.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: